CME Instructions

Vardiman J.W. , Brunning R.D. , Arber D.A. . Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow S.H. , Campo E. , Harris N.L. , eds. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008: 18–30.

Cervantes F. , Dupriez B. , Pereira A. . New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113(13): 2895–2901.

Lichtman M.A. , Tefferi A. . Primary myelofibrosis. In: Kaushansky K. , Lichtman M.A. , Beutler E. , eds. Williams Hematology. 8th ed. New York, NY: McGraw Hill Medical; 2010: 1381–1399.

Vannucchi A.M. . Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011; 2011: 222–230.

Tefferi A. . How I treat myelofibrosis. Blood. 2011; 117(13): 3494–3504.

Data on file: Incyte Corporation. http://jakafi.com/myelofibrosis.aspx. Accessed August 26, 2012.

Rollison D.E. , Howlader N. , Smith M.T. . Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1): 45–52.

Tefferi A. , Vainchenker W. . Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011; 29(5): 573–582.

Jakafi (ruxolitinib) [package insert]. Wilmington, DE: Incyte Corporation; 2011.

Verstovsek S. , Kantarjian H. , Mesa R.A. . Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010; 363(12): 1117–1127.

Verstovsek S. , Mesa R.A. , Gotlib J. . A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9): 799–807.